[1] Vitale G, Gitto S, Vukotic R, et al. Familial intrahepatic cholestasis: New and wide perspectives. Dig Liver Dis, 2019, 51(7):922-933. [2] Bryson TE, Anglin CM, Bridges PH, et al. Nuclease-mediated gene therapies for inherited metabolic diseases of the liver. Yale J Biol Med, 2017, 90(4):553-566. [3] Bull PC, Thomase GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting p-type atpase similar to the menkes gene. Nat Genet, 1993, 5(4):327-337. [4] Daniel FW, James SD. Atp7b variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease. Hum Genet, 2020, 139(8):1065-1075. [5] Marie F, Caroline D. The psychopharmacology of Wilson disease and other metabolic disorders. Handb Clin Neurol, 2019, 165(1):191-205. [6] Chia YW, Jodie LB. Liver iron sensing and body iron homeostasis. Blood, 2019, 133(1):18-29. [7] Grosse SD, Gurrin LC, Bertalli NA, et al. Clinical penetrance in hereditary hemochromatosis: Estimates of the cumulative incidence of severe liver disease among hef c282y homozygotes. Genet Med, 2018, 20(4):383-389. [8] Wagner KH, Shiels RG, Lang CA, et al. Diagnostic criteria and contributors to Gilbert's syndrome. Crit Rev Clin Lab Sci, 2018, 55(2):129-139. [9] 白洁,郑素军. 重视和推进对遗传代谢性肝病的认识和研究. 实用肝脏病杂志, 2021, 24(2):153-155. [10] Manlio T, Claudia C, Maria M, et al. Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome. J Clin Pharm Ther, 2019, 44(6):985-987. [11] Mitchell E, Gilbert M, Loomes KM. Alagille syndrome. Clin Liver Dis, 2018, 22(4):625-641. [12] Baker A, Kerkar N, Todorova L, et al. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol, 2019, 43(1):20-36. [13] Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis, 2004, 8(1):133-149. [14] 汪佩文, 董育玮, 李郑红, 等. 94例不明原因肝功能异常患者临床与肝组织病理学分析. 实用肝脏病杂志, 2018, 21(2):225-228. [15] Stenson PD, Mort M, Ball EV, et al. The human gene mutation database: Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet, 2017, 136(6):665-677. [16] Kajihara S, Matsuhashi S, Yamamoto K, et al. Exon redefinition by a point mutation within exon 5 of the glucose-6-phosphatase gene is the major cause of glycogen storage disease type 1a in Japan. Am J Hum Genet, 1995, 57(3):549-555. [17] 白洁, 任艳, 梁晨, 等. 1996~2020年北京佑安医院遗传代谢性肝病住院患者流行病学特征分析. 实用肝脏病杂志, 2021, 24 (2):164-167. [18] Lei KJ, Shelly LL, Pan CJ, et al.Mutations in the glucose-phosphatase gene that cause glycogen storage disease type 1a.Science, 1993, 262(5133):580-583. [19] Reem D, Ayman S, Shatha G, et al. Periodontal manifestation of type 1b glycogen storage disease: A rare case report. Clin Adv Periodontics, 2020, 10(3):150-154. [20] Naim A, Samer G. A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opin Investig Drugs, 2021, 30(3):237-244. |